Table 1 Characteristics of included studies and quality evaluation of documents
Study | Study | Country | male,% | Age mean(SD) | NLR grouping | Follow-up (days) | Observation index | Quality score |
|---|---|---|---|---|---|---|---|---|
Akpek, [7] 2012 | Prospective cohort study | Turkey, China, USA | 327(78.0) | 59.4 ± =12.4 | ≤3.3 > 3.3 | 6.7(mean) | In-hospital: in-stent thrombosis, MACE, nonfatal MI, no reflow, all-cause mortality | 6 |
Arbel, [8] 2014 | Prospective cohort study | Israel | 436(81.0) | 61 ± 13 | <  6.5 ≥6.5 | 1044 (median) | In-hospital: arrhythmia Long-term: all-cause mortality | 6 |
Han, [9] 2013 | Prospective cohort study | Korea | 247(75.8) | 61.9 ± 12.3 | ≤3.30 3.31–6.52 > 6.53 | 360(total) | In-hospital: MACE, nonfatal MI, no reflow, all-cause mortality Long-term: nonfatal MI, MACE, all-cause mortality | 5 |
He, [10] 2014 | Prospective cohort study | China | 546(78.9) | 60.27 | < 3.16 3.16–4.75 > 4.75 | 3395 (median) | In-hospital: arrhythmia, no reflow, cardiac mortality, all-cause mortality Long-term: cardiac mortality, all-cause mortality, MACE | 5 |
Her, [11] 2017 | Prospective cohort study | Korea | 140(81.4) | 57.1 ± 12.4 | < 5.8 ≥5.8 | 1230(median) | In-hospital: MACE 12 months follow-up: MACE, Long-term: all-cause mortality, nonfatal MI | 6 |
Park JinJoo, 2013 [12] | Prospective cohort study | Korea | 235(72.0) | 60.9 ± 13.9 | < 5.44 ≥5.44 | 1092(median) | Long-term: all-cause mortality | 6 |
Kaya, [13] 2013 | Prospective cohort study | Turkey, China, USA | 535(78.4) | 60.8 | < 2.3 2.3–4.4 > 4.4 | 1299(median) | In-hospital: in-stent thrombosis, MACE, non-fatal MI, no reflow, cardiac mortality, Long-term: Non-fatal MI,MACE, cardiac mortality | 6 |
Pan, [14] 2015 | Prospective cohort study | China | 496(78.0) | 59.27 ± 11.27 | <  3.0 3.0–6.40 >  6.40 | 360(total) | In-hospital: angina, arrhythmia, cardiac mortality, 12 months follow-up: all-cause mortality | 6 |
Sen, [15] 2013 | Prospective cohort study | Turkey | 176(86.3) | 55.8 | <  3.30 3.30–4.56 > 4.56 | 1140 (total) | In-hospital: all-cause mortality, MACE, no reflowAt three-year follow up, all-cause mortality, MACE | 6 |
Shen, [16] 2010 | Prospective cohort study | China | 329(59.7) | 61 | 1.44–3.45 3.45–4.81 4.82–6.46 6.47–22.57 | 1898 (median) | In-hospital: all-cause mortality Long-term: all-cause mortality | 6 |
Tanriverdi, [17] 2017 | Prospective cohort study | Turkey | 285(77.4) | 59.6 | < 5.47 ≥ 5.47 | 3.8(mean) | In-hospital: all-cause mortality | 6 |
Zuin, [18] 2017 | Prospective cohort study | Italy | 1724(71.8) | 64.5 | < 2.1 3.4–4.1 > 4.1 | 363(median) | Long-term: cardiovascular mortality | 6 |
Ergelen, [19] 2014 | Retrospective cohort study | Turkey | 2015(83.6) | 56.4 | ≤6.97 > 6.97 | 630 (median) | In hospital: AHF, MACE, nonfatal MI, no reflow, cardiovascular mortality, Long-term: MACE, nonfatal MI, cardiovascular mortality | 5 |
Gazi, [20] 2015 | Retrospective cohort study | Turkey | 417(79.9) | 62.57 | ≤5.77 > 5.77 | 5.7(mean) | In-hospital: AHF, angina, arrhythmia, all-cause mortality, nonfatal MI | 6 |